Department of Gynecologic Oncology, Insular Materno-Infantil University Hospital, Las Palmas, Spain;
Universidad de Las Palmas de Gran Canaria (ULPGC), Las Palmas, Spain.
Anticancer Res. 2024 Oct;44(10):4413-4418. doi: 10.21873/anticanres.17270.
BACKGROUND/AIM: To investigate the factors related to non-reversal of ostomy after cytoreductive surgery in ovarian cancer. In many women with ovarian cancer, transitory ostomies are performed to limit the consequences of anastomotic leak. Although intended to be temporary, a proportion of these ostomies might never be reversed.
This was a retrospective study of patients with 2014 International Federation of Obstetrics and Gynecology stage IIB-IVB ovarian cancer requiring a transitory ostomy during primary or secondary cytoreductive surgery at the Bergonie Institute, France, and the University Hospital of Las Palmas, Spain, between January 2012 and December 2022. Rate of ostomy reversal, its timing (weeks) and postoperative complications were assessed. Multivariate logistic regression analysis was performed to identify limiting factors for ostomy reversal.
During the study period, we reviewed data on 181 consecutive patients with ovarian cancer with transitory ostomy creation; 89 (49.2%) patients were not candidates for an ostomy reversal surgery because of disease progression (n=65), death (n=16), and patient's refusal of surgery (n=8). A total of 92 patients were candidates for reversal surgery and were therefore included in the final analysis. In total, 57 (62%) patients had their ostomy reversed. The mean time from ostomy creation to ostomy closure was 47.7 (standard deviation=33.1) weeks. Hartmann's procedure (leaving a rectal stump of 5-6 cm) was identified as an independent predictive factor for non-reversal of ostomy (odds ratio=6.42, 95% confidence interval=1.61-25.53; p=0.008). Complications after ostomy reversal occurred in 32 patients (34.8%).
Hartmann's procedure is a limiting factor for ostomy reversal in patients with ovarian cancer. We recommend avoiding Hartmann's procedure during cytoreductive surgery, even after colorectal anastomotic leak.
背景/目的:研究卵巢癌细胞减灭术后造口无法逆转的相关因素。在许多卵巢癌女性患者中,为了限制吻合口漏的后果,会进行暂时性造口术。虽然这些造口术旨在是临时的,但其中一部分可能永远无法逆转。
这是一项回顾性研究,纳入了 2014 年国际妇产科联合会(FIGO)分期为 IIB-IVB 期的卵巢癌患者,这些患者在法国 Bergonie 研究所和西班牙拉斯帕尔马斯大学医院接受初次或二次细胞减灭术时需要进行暂时性造口术,时间为 2012 年 1 月至 2022 年 12 月。评估造口逆转率、时机(周数)和术后并发症。采用多变量逻辑回归分析来确定造口逆转的限制因素。
在研究期间,我们回顾了 181 例卵巢癌患者行暂时性造口术的数据;89 例(49.2%)患者由于疾病进展(n=65)、死亡(n=16)和患者拒绝手术(n=8)而不适合进行造口逆转手术。共有 92 例患者适合进行逆转手术,因此被纳入最终分析。共有 57 例(62%)患者进行了造口逆转。从造口建立到关闭的平均时间为 47.7(标准差=33.1)周。Hartmann 手术(直肠残端保留 5-6cm)被确定为造口无法逆转的独立预测因素(比值比=6.42,95%置信区间=1.61-25.53;p=0.008)。造口逆转后发生并发症的有 32 例(34.8%)。
Hartmann 手术是卵巢癌患者造口无法逆转的限制因素。我们建议在进行细胞减灭术时避免 Hartmann 手术,即使发生了结直肠吻合口漏。